"Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism"
NEJM Mar 21
http://www.nejm.org/doi/full/10.1056/NEJMoa1211716?query=featured_home
"CONCLUSIONS

Closure of a patent foramen ovale for secondary prevention of cryptogenic embolism did not result in a significant reduction in the risk of recurrent embolic events or death as compared with medical therapy. (Funded by St. Jude Medical; ClinicalTrials.gov number,NCT00166257.)"